• Psyence Biomedical’s Texas unit, Texas Ibogaine Research Corp, signed a manufacturing services agreement with Benuvia to produce pharmaceutical-grade ibogaine API in the US.
• Benuvia’s 83,000-square-foot Round Rock, Texas site is DEA-registered for controlled-substance manufacturing from development through commercial-scale production.
• The arrangement supports TIRC’s planned US development program, linking licensed ibogaine supply from PsyLabs with domestic cGMP manufacturing capacity.
• Benuvia is advancing DEA import-permit and procurement-quota applications; production timing hinges on DEA quotas and other regulatory authorizations.
• Benuvia estimates it holds about half of the US aggregate production quota for ibogaine, underpinning potential domestic output if quotas expand.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Psyence Biomedical Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-106630), on October 05, 2026, and is solely responsible for the information contained therein.